A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension

Trial Profile

A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial hypertension

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Bosentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms FUTURE 6
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2017 New trial record
    • 09 Dec 2016 As per the correspondence between Actelion Clinical Trial Disclosure Team and EudraCT registration desk dated 9 Dec 2016, this trial was never initiated and no patients were included in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top